Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Brentuximab Vedotin + Chemo for AML

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Massachusetts General Hospital
Sponsor:
Information provided by (Responsible Party):
Amir Fathi, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01830777
First received: April 3, 2013
Last updated: October 1, 2014
Last verified: May 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)